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Background: Vitamin D is associated with lung function in cross-sectional studies, and vitamin D inadequacy is
hypothesized to play a role in the pathogenesis of chronic obstructive pulmonary disease. Further data are needed
to clarify the relation between vitamin D status, genetic variation in vitamin D metabolic genes, and cross-sectional
and longitudinal changes in lung function in healthy adults.
Methods: We estimated the association between serum 25-hydroxyvitamin D [25(OH)D] and cross-sectional forced
expiratory volume in the first second (FEV1) in Framingham Heart Study (FHS) Offspring and Third Generation
participants and the association between serum 25(OH)D and longitudinal change in FEV1 in Third Generation
participants using linear mixed-effects models. Using a gene-based approach, we investigated the association
between 241 SNPs in 6 select vitamin D metabolic genes in relation to longitudinal change in FEV1 in Offspring
participants and pursued replication of these findings in a meta-analyzed set of 4 independent cohorts.
Results: We found a positive cross-sectional association between 25(OH)D and FEV1 in FHS Offspring and Third
Generation participants (P = 0.004). There was little or no association between 25(OH)D and longitudinal change in
FEV1 in Third Generation participants (P = 0.97). In Offspring participants, the CYP2R1 gene, hypothesized to influence
usual serum 25(OH)D status, was associated with longitudinal change in FEV1 (gene-based P < 0.05). The most
significantly associated SNP from CYP2R1 had a consistent direction of association with FEV1 in the meta-analyzed
set of replication cohorts, but the association did not reach statistical significance thresholds (P = 0.09).
Conclusions: Serum 25(OH)D status was associated with cross-sectional FEV1, but not longitudinal change in FEV1.
The inconsistent associations may be driven by differences in the groups studied. CYP2R1 demonstrated a gene-based
association with longitudinal change in FEV1 and is a promising candidate gene for further studies.
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Decreased lung function due to airflow obstruction is the
primary characteristic of chronic obstructive pulmonary
disease (COPD), the 3rd leading cause of mortality in the
United States [1]. Vitamin D status, assessed by the circu-
lating serum biomarker 25-hydroxyvitamin D [25(OH)D],
plays a well-known role in bone health, and is also* Correspondence: pac6@cornell.edu
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tion [2, 3]. National surveys estimate that over 30 % of
Americans are at risk for vitamin D insufficiency (defined
as serum 25(OH)D <20 ng/mL) [3, 4]. Vitamin D is ob-
tained through sun exposure and diet [2], and genome-
wide association studies (GWAS) have identified single
nucleotide polymorphisms (SNPs) in vitamin D metabolic
genes that are significantly associated with serum 25(OH)D
concentrations [5, 6].
The active vitamin D metabolite, 1,25(OH)2D, is con-
stitutively synthesized from 25(OH)D in vitro in renal
and extra-renal tissues including lung tissue [7] and isis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Hansen et al. Respiratory Research  (2015) 16:81 Page 2 of 8involved in biological processes critical to lung function
including inflammation and airway remodeling [8–10].
Several cross-sectional, population-based observational
studies have demonstrated strong, positive associations
between vitamin D levels and lung function [11–13], al-
though one study in the Hertfordshire cohort did not
replicate cross-sectional associations [14]. Additionally,
vitamin D deficiency is common in COPD patients [15],
and high-dose vitamin D supplementation reduced COPD
exacerbations in patients with severe vitamin D deficiency
[16]. High vitamin D levels have also been associated with
reduced risk of respiratory infections [13, 17], although
randomized controlled trials of vitamin D supplemen-
tation and respiratory infections have been inconclusive
[18, 19]. A recent cohort study demonstrated that low
serum vitamin D was associated both with steeper lung
function decline and a higher risk of developing COPD
[20]. Additionally, an observational study in COPD pa-
tients reported no association between serum 25(OH)D
and longitudinal lung outcomes [21], but a recent
population-based study in an elderly male cohort reported
steeper lung function decline in current smokers with
serum 25(OH)D ≤20 ng/mL versus smokers with higher
25(OH)D [22]. Genetic variants in the vitamin D binding
protein, encoded by the GC gene, are associated with COPD
risk [15, 23–26], and GC may be an important mediator of
hypothesized vitamin D effects on lung function [27].
Our study investigated the association of serum
25(OH)D with lung function in two generational co-
horts of the Framingham Heart Study (FHS). Both
serum measurements of vitamin D and genetic variants
associated with serum vitamin D levels were investi-
gated in association with cross-sectional FEV1 and rate
of change in FEV1. Overall, this study provides a com-
prehensive exploration of serum 25(OH)D associations
with FEV1 in a healthy, adult population-based sample
including both men and women.
Methods
Study design
We investigated the association of serum 25(OH)D with
lung function in two Framingham Heart Study (FHS)
generational cohorts, the Offspring cohort and the Third
Generation cohort. The availability of the specific data
needed for the stages of the research was the main driver
of which cohort(s) contributed to each analysis. We pur-
sued replication of the SNP findings in four independent
epidemiologic cohort studies, namely the Health, Aging
and Body Composition Study (Health ABC), the Coron-
ary Artery Risk Development in Young Adults Study
(CARDIA), the Busselton Health Study (BHS), and the
Cardiovascular Health Study (CHS), and we investigated
the SNPs in relation to serum 25(OH)D status in the
SUNLIGHT consortium [6].Study population and ethics
Study participants were from the Offspring and Third
Generation cohorts of the FHS, a longitudinal family-
based study established in 1948 in Framingham, MA.
The Offspring cohort, consisting of original cohort off-
spring and their spouses, began in 1971 [28]. The Third
Generation cohort was initiated in 2002, enrolling chil-
dren of the Offspring cohort [29]. Self-reported ethnicity
across all FHS cohorts was >99 % Caucasian [29].
Third Generation participants with serum 25(OH)D
measurements from Exam 1 (2002–2005) and spirom-
etry measurements from Exams 1 and 2 (2008–2010)
were included in all serum 25(OH)D—FEV1 analyses (N
= 3,599; 88 % of full cohort). 1,435 Offspring participants
(28 % of full cohort) had serum 25(OH)D and spirom-
etry measurements at either Exam 6 (1995–1998) or 7
(1998–2001), and were included in the cross-sectional
serum 25(OH)D—FEV1 analyses. The Offspring partici-
pants were not included in the serum 25(OH)D—rate of
change in FEV1 analysis because only 24 % of the full
Offspring cohort had repeated lung function measured
after serum vitamin D, and we expected survivor bias to
affect the longitudinal associations (see Results section).
Serum vitamin D and pulmonary function were mea-
sured concurrently in Offspring participants, and thus
the Offspring cohort data contributed to estimation of
the cross-sectional association. If any bias exists, it is ex-
pected to be conservative (estimate closer to the null
value) because the range in vitamin D may be restricted
in the subsample with data. The SNP—rate of change in
FEV1 associations were studied in 3,230 Offspring par-
ticipants (63 % of full cohort) with GWAS genotype
data and spirometry measurements spanning over
Exams 5–8, which provided optimal information on
longitudinal change in lung function given the number
of repeated measurements and the length of time be-
tween measurements.
All study participants provided written informed con-
sent for this study, and local institutional review boards
approved the study protocols.
Measures
Genotyping was performed using the Affymetrix 500 K
SNP array with a supplemental Affymetrix 50 K gene-
focused array. Genotyping and imputation methods are
described in detail elsewhere [6, 30]. 241 imputed SNPs
in six candidate genes with well-established roles in vita-
min D metabolism and transport [CYP24A1, CYP27A1,
CYP27B1, CYP2R1, DHCR7/NADSYN1 (these two genes
considered jointly as a candidate genomic locus due to
prior GWAS associations [5, 6]), and GC] were ana-
lyzed (+/− 5 KB region on either end of genes included;
Additional file 1: Table S1 for details).
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can Thoracic Society/European Respiratory Society cri-
teria for acceptability and reproducibility were used [31]
(see Additional file 1 for further details).
Serum 25(OH)D was measured using radioimmuno-
assay (DiaSorin Inc, Stillwater, MN, USA) [6, 32, 33],
and log-transformed values were used in all analyses (see
Additional file 1 for further details). Offspring serum
samples for 25(OH)D were collected between 1997–
2001 [32] and Third Generation serum samples between
2001–2005 [6, 33]; assays were completed separately in
different laboratories. However, all FHS samples were
analyzed after 1998, so assay drifts due to the reformu-
lated RIA assay, described for the NHANES data [34],
are not expected to affect 25(OH)D measurements in
Framingham (Additional file 1 for further quality control
information on assays).
Smoking pattern was defined as: persistent smoker
(current smoker, all time points during follow-up),
intermittent smoker (current smoker at ≥ 1 time point),
former smoker (former smoker, all time points), and
never smoker (never smoker, all time points).
Statistical analysis
All analyses used linear mixed effect models with a ran-
dom effect to account for familial correlation. The inde-
pendent variable was FEV1; in serum 25(OH)D—rate of
change in FEV1 analyses, the coefficient of interest was
the interaction of 25(OH)D x time (time = time elapsed
between the initial FEV1 measurement and each subse-
quent measurement), which estimated the effect of serum
25(OH)D on rate of change in FEV1. The cross-sectional
association of serum 25(OH)D with FEV1 was estimated
by the coefficient for serum 25(OH)D from the mixed
effect models; all participants with serum 25(OH)D had
a concurrent measurement of pulmonary function. In
SNP—rate of change in FEV1 analyses, the coefficient
for the interaction of SNP x time estimated the additive
effect of the coded allele on rate of change in FEV1. All
models were adjusted for baseline age, sex, height,
current smoking status, smoking pattern during follow-
up (defined in previous paragraph), the interaction of
smoking pattern x time, and baseline pack-years. Serum
25(OH)D—FEV1 models were further adjusted for month
of 25(OH)D measurement, body mass index (BMI), and
FHS cohort (for models including both Offspring and
Third Generation participants). Genetic models were fur-
ther adjusted for the first two ancestry principal compo-
nents to account for population substructure [35]. Analyses
were completed using R (version 2.15.3).
A staged approach was used for SNP—FEV1 analyses.
First, a gene-based P-value was calculated for the associ-
ation of each candidate gene with rate of change in FEV1
using the VEGAS program [36, 37]. VEGAS calculates asingle, gene-based test statistic based on P-values from
the SNP—rate of change in FEV1 regression analysis
across a given gene region, taking the linkage disequilib-
rium (LD) structure of the gene into account [36]. A
gene-based P-value < 0.05 was chosen to select genes to
follow-up in replication. Second, the most significant
SNP from candidate genes with a gene-based P < 0.05
was assessed for replication in a meta-analysis of the
four replication cohorts. The most significant SNP from
each gene with a gene-based P < 0.05 was further evaluated
for association with serum 25(OH)D using data from the
SUNLIGHT consortium, which comprised 33,996 individ-
uals of European ancestry, including FHS participants,
with GWAS data and the serum 25(OH)D phenotype [6].Results
Average serum 25(OH)D in the 28 % of the Offspring
participants with data was 18.0 ng/mL, compared with
34.5 ng/mL in Third Generation participants; similarly,
the proportion of participants at risk of vitamin D defi-
ciency (defined as serum 25(OH)D <12 ng/mL) was
14.4 % and 1.2 % in the Offspring and Third Generation
cohorts, respectively (Table 1). As expected, Offspring
participants were older, had lower baseline FEV1, and
were more likely to be former smokers than the Third
Generation participants (Tables 1 and 2).25(OH)D associations with cross-sectional FEV1 and rate
of change in FEV1
25(OH)D was positively associated with FEV1 in the
cross-sectional analysis of the combined sample of Off-
spring and Third Generation participants, such that a 1-
unit increase in log-transformed 25(OH)D was associated
with a 45 mL increase in FEV1 (P = 0.004) (Table 3). A
consistent direction of association was observed for the di-
chotomous vitamin D variable at thresholds of <12 ng/mL
or <20 ng/mL, using the Institute of Medicine thresholds
for risk of vitamin D deficiency and inadequacy, respect-
ively [3], but coefficients for the dichotomous serum vita-
min D variables did not reach the significance threshold of
P < 0.05. The spline analysis estimating the cross-sectional
serum 25(OH)D—FEV1 association showed an approxi-
mately linear, positive association for serum 25(OH)D <
12 ng/mL. In the 12 to 40 ng/mL range, the serum
25(OH)D—FEV1 association attenuated, and a plateau was
reached above a threshold of about 40 ng/mL (Fig. 1). The
pattern of association did not differ between Offspring
and Third Generation participants (sub panels of Fig. 1),
and the estimates of the linear serum 25(OH)D—FEV1 as-
sociation were about the same in both cohorts (beta coef-
ficient for serum 25(OH)D—FEV1 association was 37 (SE:
29, P = 0.20) and 34 (SE: 19, P = 0.08) mL in Offspring and
Third Generation, respectively).
Table 1 Baseline1 population characteristics of Framingham Heart Study participants
25(OH)D—FEV1 Analyses Offspring Cohort Third Generation Cohort P-value
2
N in analysis N = 1,435 N = 3,599
FEV1, L 2.7 (0.8) 3.6 (0.8) <0.0001
Follow-up duration, yr3 7.2 (1.9) 6.1 (0.6) <0.0001
Baseline age, yr 59.9 (9.2) 40.2 (8.7) <0.0001
Male, % 48 47 0.84
Height, cm 168.0 (9.1) 170.6 (9.3) <0.0001
Baseline pack-years 26.0 (22.7) 13.7 (14.2) <0.0001
Current smokers4, % 12.8 15.2 0.02
Former smokers4, % 50.8 27.0 <0.0001
BMI 28.0 (5.1) 26.9 (5.4) <0.0001
25(OH)D, ng/ml5 18.0 (1.5) 34.5 (1.5) <0.0001
N at risk of 25(OH)D deficiency (<12 ng/mL), % 207 (14.4 %) 44 (1.2 %) <0.0001
N at risk of 25(OH)D inadequacy (<20 ng/mL), % 801 (55.8 %) 311 (8.6 %) <0.0001
1Baseline measurements are from the exam at time of vitamin D measurement (either Exam 6 or 7 for Offspring, and Exam 1 for Third Generation); Participant
characteristics listed as mean (SD) for continuous variables and number (%) for categorical variables
2P-values for continuous variables calculated from unpaired t-test; P-values for categorical variables calculated from chi-square test
3Follow-up duration of spirometry measurements subsequent to serum 25(OH)D measurement; average duration calculated for N = 1,223 Offspring cohort participants
with longitudinal spirometry and N = 2,894 Third Generation cohort participants
4Current smokers at baseline; former smokers at all time points
5Geometric mean of 25(OH)D
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longitudinal analysis: the 24 % of Offspring cohort mem-
bers with both serum 25(OH)D measurements and sub-
sequent repeated FEV1 measurements had a much lower
rate of change in FEV1 compared to the 63 % of Off-
spring cohort members with only longitudinal lung func-
tion data (see Additional file 1 for details). Thus, we
estimated the serum 25(OH)D—rate of change in FEV1
association in Third Generation cohort participants only.
There was little or no association between serum 25(OH)D
and rate of change in FEV1 (P = 0.97; Table 4). Neither was
there any statistical evidence for a differential effect ofTable 2 Baseline1 population characteristics of Framingham
Heart Study participants contributing to SNP analysis
SNP—FEV1 Analysis Offspring Cohort
N in analysis N = 3,230
FEV1, L 3.0 (0.8)
Follow-up duration, yr 14.7
Baseline age, yr 50.9 (10.3)
Male, % 47
Height, cm 165.5 (9.5)
Baseline pack-years 25.4 (21.3)
Current smokers2, % 24.6
Former smokers2, % 39.8
1 Baseline measurements refer to Exam 5; Participant characteristics listed as
mean (SD) for continuous variables and number (%) for categorical variables
2 Current smokers at baseline; former smokers at all time pointsserum 25(OH)D on rate of change in FEV1 by smoking
status.
Vitamin D metabolic gene SNPs and rate of change in
FEV1
We explored the association of SNPs in select vitamin D
metabolic genes with rate of change in FEV1 in Off-
spring participants, and two genes, namely CYP27B1
and CYP2R1, were associated with rate of change in
FEV1 at a nominal gene-based P < 0.05. The most signifi-
cant SNP associations in CYP27B1 and CYP2R1 were for
rs10877013 (P = 0.02) and rs11819875 (P = 0.004), re-
spectively, and the minor alleles of these SNPs were as-
sociated with steeper FEV1 decline (Table 5). No other
candidate genes met the threshold for gene-based statis-
tical significance (P < 0.05), and thus none were consid-
ered further.
We explored replication of the most significant SNP in
CYP27B1 and CYP2R1 with change in FEV1 in a meta-
analyzed set of four independent cohorts. Rs11819875
(CYP2R1) showed a consistent direction of association
with FEV1 in FHS and the meta-analyzed set of replica-
tion cohorts, but this association was not replicated by
statistical significance thresholds (β = −1.0, 95 % CI: −2.2,
0.2, P = 0.09; Table 5 and Additional file 1: Table S2).
Rs11819875 was associated with a lower concentration of
serum 25(OH)D in data from the SUNLIGHT consortium
(P = 0.15 from combined SUNLIGHT discovery and repli-
cation cohorts). Rs10877013 in CYP27B1 showed little to
no association with rate of change in FEV1 in the meta-
Table 3 Cross-sectional multivariable association of 25(OH)D with baseline FEV1 (mL) in the Offspring and Third Generation cohorts,
combined (N = 5,034)
Model categorization of vitamin D: β SE P
Continuous : Log-transformed 25(OH)D 45.2 15.5 0.004
Dichotomy 1: At risk of vitamin D deficiency (<12 ng/mL) vs. not −46.7 26.7 0.08
Dichotomy 2: At risk of vitamin D inadequacy (<20 ng/mL) vs. not −30.6 16.6 0.07
Adjusted for: baseline age, sex, height, smoking pattern, current smoking status, baseline pack-years, FHS cohort, baseline BMI, and month of blood draw; all coefficients
show expected direction of effect
β beta coefficient, SE standard error, P P-value
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P = 0.40; Table 4), and rs10877013 was associated with
lower 25(OH)D in SUNLIGHT (P = 0.11 from combined
SUNLIGHT discovery and replication cohorts).
Discussion
In this population-based cohort study of adults, we in-
vestigated the association of vitamin D with cross-
sectional FEV1 and longitudinal FEV1, considering both
serum 25(OH)D status and genetic variants in selected
vitamin D metabolic genes. We demonstrated a strong,
positive cross-sectional association of serum 25(OH)D
with FEV1, consistent with the findings of most previ-
ously published studies [11–13, 20]. However, serum
25(OH)D was not associated with longitudinal change in
FEV1 in Third Generation participants. CYP2R1, a vitaminFig. 1 Spline analysis of log-transformed 25(OH) D by residual FEV1D metabolism gene hypothesized to influence usual
25(OH)D status, was associated with longitudinal change
in FEV1 in a gene-based analysis, but the most significant
SNP in this gene was not replicated in a meta-analyzed set
of replication cohorts.
Our cross-sectional findings provide evidence that as-
sociations between 25(OH)D and lung function may be
non-linear and limited to individuals with inadequate
vitamin D status. The lack of association of serum
25(OH)D with longitudinal change in FEV1 may be ex-
plained by characteristics of the study population; the
Third Generation cohort was comprised of middle-aged
participants with excellent serum 25(OH)D status. More
than 90 % of the Third Generation cohort participants
had sufficient serum 25(OH)D [25(OH)D > 20 ng/mL]
and only 8.6 % and 1.2 % were considered to be at risk
Table 4 Association of 25(OH)D with rate of change in FEV1 (mL/yr) in the Third Generation cohort
Third Generation Cohort
(N = 3,599)
Model parameterization of vitamin D: β SE P
Continuous : Log-transformed 25(OH)D −0.06 1.7 0.97
Dichotomy 1: At risk of vitamin D deficiency (<12 ng/mL) vs. nota −0.02 6.9 0.997
Dichotomy 2: At risk of vitamin D inadequacy (<20 ng/mL) vs. not 2.0 2.5 0.41
Adjusted for: baseline age, sex, height, smoking pattern over follow-up and its interaction with time, baseline pack-years, current smoking status at each time
point, BMI, and month of blood draw
β beta coefficient for 25(OH)D x time effect, SE standard error, P P-value
aInterpretation: Third Generation participants at risk of vitamin D deficiency have a 0.02 mL/yr steeper rate of decline compared to Third Generation participants
not at risk of deficiency
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respectively (thresholds defined by the IOM [3]). Given
possible non-linear associations and/or threshold ef-
fects, our findings do not rule out a longitudinal vita-
min D status—rate of change in pulmonary function
association limited to persons at risk of inadequacy
and/or deficiency.
Supporting this hypothesis, a recent study showed that
individuals in the lowest quintile of serum 25(OH)D had
a steeper rate of lung function decline compared with
individuals in the highest quintile, where the mean in
the highest quintile was 30 ng/mL [20]. In comparison,
in our analysis of the Third Generation Framingham
Heart Study cohort, the majority of the participants
(>90 %) had serum 25(OH)D > 20 ng/mL. The recent
finding of steeper decline limited to participants with
the lowest serum 25(OH)D [20] and the lack of associ-
ation in our analysis highlight the importance of consid-
ering non-linear associations and thresholds of effect
defined by baseline nutritional status in future studies of
25(OH)D status and lung function.
A SNP in CYP2R1 (rs11819875) was associated with
rate of change in FEV1 in FHS, but did not show statisti-
cally significant evidence for replication of the associ-
ation in a meta-analysis of four independent cohort
studies (P = 0.09). However, the β-coefficient for this
SNP was in the same direction in 3 of the 4 cohorts, and
rs11819875 was associated with lower 25(OH)D in the









Best SNP Position Coded
Allelea
Fre
CYP27B1 0.02248 12 5 rs10877013 56451352 T 0.3
CYP2R1 0.04417 11 15 rs11819875 14873873 G 0.1
Adjusted for: baseline age, sex, height, smoking pattern over follow-up and its inter
components for genetic ancestry
Chr chromosome, SNP single nucleotide polymorphism, β beta coefficient for SNP x
aCoded allele and frequency for the Framingham Heart Study (FHS). All effect estim
FHS and replication cohorts were nearly identicalnear the threshold, and sample size, heterogeneity in en-
vironmental factors affecting usual vitamin D status (for
example, sun exposure), and/or heterogeneity in the out-
come measure (rate of change in FEV1) may contribute
to the lack of replication. CYP2R1 is a key hepatic 25-
hydroxylase enzyme [38], and variants in this gene are
consistently associated with 25(OH)D status in GWAS
[5, 6]; this gene is a promising candidate for further
studies investigating the role of vitamin D status in lung
function phenotypes.
Our study has strengths and limitations. A limitation
of the serum 25(OH)D—FEV1 analysis is that serum
25(OH)D was measured only once and a single measure-
ment of vitamin D may not adequately estimate the long-
term usual vitamin D status. We assumed that 25(OH)D
measured at one point in time provided a reasonable ap-
proximation of 25(OH)D status throughout follow-up
given that 25(OH)D measurements 12 months apart are
highly correlated (r = 0.8 [39]) and given the relatively
short follow-up period of 6–7 years. A related limita-
tion is that supplement use data were not available,
thus we could not investigate whether low serum
25(OH)D measures were associated with subsequent
supplement use. While spirometry measurements in
the Third Generation cohort were separated by an aver-
age of 6.1 years, a longer follow-up and more outcome
measurements may be needed to identify associations
between vitamin D and rate of change in FEV1. The
Offspring participants included in the genetic analysisith the rate of change in FEV1 in FHS and in the meta-analyzed
q FHS (N = 3,230) Meta-analyzed replication cohorts (N = 7,246)
β SE P β SE P
0 −1.3 0.5 0.02 −0.4 0.5 0.40
8 −1.9 0.7 0.004 −1.0 0.6 0.09
action with time, baseline smoking pack-years, and the first two principal
time effect, SE standard error, P P-value
ates presented in terms of FHS coded allele. Coded allele frequencies between
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leading to increased precision in the rate of decline es-
timates for the SNP—rate of change in FEV1 analysis.
While the genetic analyses described in this study bor-
row concepts from the Mendelian Randomization (MR)
literature [40], the limitations of the available data, in-
cluding limited sample size, precluded a formal MR
analysis. Overall, a major strength is the use of data
from the Framingham Heart Study cohort, which pro-
vided a large, healthy, population-based sample includ-
ing both men and women.
Conclusions
The findings from this study suggest that serum
25(OH)D—FEV1 associations may be limited to indi-
viduals with inadequate 25(OH)D. Further, these find-
ings suggest important study design considerations
regarding potential to benefit from nutritional advice
and/or intervention in future studies of 25(OH)D and
lung function. Results of the SNP—FEV1 analysis dem-
onstrate that genetic variants in a vitamin D metabolic
gene are suggestively associated with rate of change in
FEV1, and our results provide evidence to guide future
studies.
Additional file
Additional file 1: Table S1. Imputed SNPs in Vitamin D Metabolic Genes
in FHS. Table S2. Replication cohort associations of the most significant
SNPs per gene with the rate of change in FEV1.
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